Dyskeratosis congenita: survival, sister-chromatid exchange and repair following treatments with crosslinking agents.
D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003432:Cross-Linking Reagents / Q000494:pharmacology*; D003434:Crossing Over, Genetic / Q000187:drug effects*; D004260:DNA Repair / Q000187:drug effects*; D003937:Diagnosis, Differential; D005199:Fanconi Anemia / Q000175:diagnosis; D005347:Fibroblasts / Q000187:drug effects; D006801:Humans; D008937:Mitomycins / Q000494:pharmacology; D012854:Sister Chromatid Exchange / Q000187:drug effects*; D012871:Skin Diseases / Q000151:congenital* / Q000235:genetics; D013577:Syndrome; D014307:Trioxsalen / Q000494:pharmacology
D003432:Cross-Linking Reagents; D008937:Mitomycins; D014307:Trioxsalen